Overview
Bioresearch Group conducts early-phase clinical trials and bioequivalence and bioavailability studies in Poland for biotechnology, pharmaceutical and CRO companies. It provides trial services from protocol design through final reporting and operates a hospital-based site with a clinic, laboratory and internal pharmacy.
Financials
Revenue history (in k)
Financial insight
- companies.financials.estonianCitCertain
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Increasing Access to Breakthrough Clinical Trials for Patients in Poland
Poland is strengthening its position as one of the leading clinical research hubs in Europe
Clinical research reshapes nicotine regulation – new publication by BRG CEO
BioResearch Group (BRG) announces the publication of a new article by Dr Katarzyna Jarus-Dziedzic.
BRG’s Contribution to the Advancement of an Innovative Therapy
Phase I clinical trials conducted at BRG play a key role in the development of new therapies
Research Conducted at BRG Presented at the 26th Warsaw Days of Academic Cardiology
Research Conducted at BRG Presented at the 26th Warsaw Days of Academic Cardiology
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-12-28. Active
41 1020 1055 0000 9902 0383 2227
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
7 public aid cases recorded, with a total value of $20,143.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 21, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Prezes Banku Gospodarstwa Krajowego | |
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezydent Miasta Stołecznego Warszawy |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, declarations on behalf of the company are made by the member of the management board. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Katarzyna Anna Jarus Dziedzic (58) | 499 | $13,506.21 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BiokineticaS.A. | $1,292,838.89 | biokinetica.com | ||
| COS LabP.S.A. | $1,275,339.79 | coslab.pl | ||
| RDLSsp. z o.o. | $880,573.67 | rdls.pl | ||
| Ecoverseasp. z o.o. | $891,022.45 | coslab.pl | ||
| Analytical R & Dsp. z o.o. | $715,583.52 | analytical.pl | ||
| Polbiotech Laboratoriumsp. z o.o. | $645,943.81 | polbiotech.pl | ||
| CTI Clinical Trial and Consulting Services Polandsp. z o.o. | $527,145.56 | ctifacts.com | ||
| Proper Medical Writingsp. z o.o. | $514,848.41 | propermedicalwriting.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| CCTSsp. z o.o. | $281,193.31 | ccts.pl |
Change history
| Date | Event | |
|---|---|---|
| 2022-11-14 | PKD change (Removed: 74.3; Added: 77.11.Z) | |
| 2016-12-13 | Entered in the register |
FAQ
Last updated: 2026-10-13